NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)

National Institutes of Health · United States government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

May 25, 2029
Response Due
Active
Status

Opportunity Overview

The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by continuing support for investigator-initiated Program Project applications. The program encourages applications for investigator-initiated program projects proposed in scientific areas relevant to the NIAID mission including the biology, pathogenesis, and host response to microbes; mechanisms regulating immune system development and function across the lifespan, and/or in response to infectious pathogens; immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, or transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.

This United States Health Services opportunity is one most of your competitors will never see.

How to bid: GlobalGov tracks this tender; it does not accept bids. Submit your response through the issuing agency’s official notice.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start a free GlobalGov account

Solicitation Details

Issuing agencyNational Institutes of Health
CountryUnited States
CategoryHealth Services
PublishedMay 07, 2026
Procurement stageRequest for Proposal (RFP)
Response dueMay 25, 2029
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedOctober 10, 2026

Source: U.S. Government (Simpler.Grants.gov) — public domain. Not affiliated with or endorsed by the United States Government.

Related Opportunities in United States

Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
Centers for Structural Biology of HIV and Other Infectious Diseases (U54 Clinical Trial Not Allowed)
Limited Competition: Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)
Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed)

See every United States Health Services opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United States Health Services intelligence report in your inbox

A personalized report on United States Health Services opportunities, emailed in 5-10 minutes. One per month, no account needed.